If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The proton:neutron ratio is not the only factor affecting nuclear stability. It depends also on evenness or oddness of its atomic number Z, neutron number N and, consequently, of their sum, the mass number A. Oddness of both Z and N tends to lower the nuclear binding energy, making odd nuclei, generally, less stable. This remarkable difference of nuclear binding energy between neighbouring nuclei, especially of odd-A isobars, has important consequences: unstable isotopes with a nonoptimal number of neutrons or protons decay by beta decay (including positron emission), electron capture, or other less common decay modes such as spontaneous fission and cluster decay. Most stable nuclides are even-proton-even-neutron, where all numbers Z, N, and A are even. The odd-A stable nuclides are divided (roughly evenly) into odd-proton-even-neutron, and even-proton-odd-neutron nuclides. Stable odd-proton-odd-neutron nuclides are the least common.
== Wine == Different bottles, nominally of the same wine, can taste and smell different. One factor is found in the variable oxygen transmission rate (OTR) of cork stoppers, which translates to a degree of bottle variation. Before the advent of inexpensive stainless steel tanks, it was not customary to blend all the wine together and bottle it at once, a process called assemblage. Instead, the winemaker would take his or her siphon from barrel to barrel and fill the bottles from a single barrel at a time. Some traditional and/or idiosyncratic wineries still do this, including Château Musar. Also, buyers and sellers of bulk wine typically do not have access to a multi-million litre tank, and so often the wine will vary depending on which tank it came from. Bottle variation that increases over time typically comes from the packaging. Exposure to heat or light can cause a wine to mature more quickly or even make it taste "cooked". Bottles aged in the chilly cellars of Sweden's alcohol monopoly are famous for tasting younger than the same wine stored at a more typical 13 °C (55 °F). Finally, not all corks seal equally well, and a faulty cork will allow air into the bottle, oxidizing it prematurely. However, a corked wine would be described as a simple fault rather than bottle variation, even though the corked bottle would be clearly different from a non-corked example. Sometimes, it is not clear what causes the variation. Bottles stored together their entire lives, with no obvious faults, can taste completely different.
After independence in 1947, India shifted from the colonial economic model to a focus on industrialisation and poverty reduction. This transition brought a large expansion of government authority. Government spending as a share of gross domestic product (GDP) increased from 3 to 5 per cent in 1931 to 22 per cent by 1981. Public administration and state-owned enterprises became major employers. To manage this market intervention, India developed—during the 1950s—a comprehensive, federally managed statistical system to conduct large-scale sample surveys for monitoring and assessing living standards or effects of interventions. The Indian state utilised fiscal policy and international assistance to fund capital-intensive industrialisation and subsidise basic goods such as food, fertilisers, and electric power. However, by the 1970s, this heavy public spending became unsustainable. Domestic economic growth slowed, leading to a balance-of-payments crisis, whereas government spending flattened around 28–30 per cent of GDP. Government-led planning yielded mixed results. Many of India’s big economic changes were not planned by government bureaucrats. Thus, the 1970s Green Revolution, mass labour migration to the Middle East, and a garment-industry boom all emerged from global market forces and non-state actors; the government simply adapted to them after they were underway. A major shift occurred during the 1990s as India rejoined the global economy. The Indian government reduced import tariffs and enacted pro-market reforms.
Sources: en.wikipedia.org
Pharmacokinetic analysis has largely taken place in live rodents as well as in rodent and human microsomes. Owing to the heterogeneity of analysis and paucity of human experiments conducted thus far, the pharmacokinetic profile of mitragynine is not complete. However, initial pharmacokinetic studies in humans have yielded preliminary information. In a study of 10 healthy volunteers taking orally administered mitragynine from whole leaf preparations, mitragynine appeared to have a much longer half-life than typical opioid agonists (7–39 hours) and reached peak plasma concentration (Tmax) within 1 hour of administration. However, another study involving a Kratom tea preparation reported a much shorter half-life of 3 hours. Mitragynine is estimated to have a bioavailability of 21%.
=== Experimental uses === As of 2016, experiments were under way for neuroblastoma, brainstem glioma, Ewing's sarcoma and Angelman syndrome. In addition, topotecan is experimentally treating non-small cell lung cancer, colorectal cancer, breast cancer, non-Hodgkin lymphoma, endometrial cancer, and oligodendroglioma.
5-Hydroxytryptamine MS Spectrum Serotonin bound to proteins in the PDB PsychoTropicalResearch Archived 7 February 2012 at the Wayback Machine Extensive reviews on serotonergic drugs and Serotonin Syndrome. Molecule of the Month: Serotonin at University of Bristol 60-Second Psych: No Fair! My Serotonin Level Is Low Archived 9 December 2023 at the Wayback Machine, Scientific American Serotonin Test Interpretation on ClinLab Navigator Archived 1 February 2010 at the Wayback Machine.
=== 1980s === Biomedical research in the 1980s was characterized by rapid advances in molecular diagnostics and genetic engineering. In 1983, Kary Mullis invented the Polymerase Chain Reaction (PCR), a technique that enabled the exponential amplification of specific DNA sequences. PCR revolutionized medical diagnostics, forensic science, and molecular genetics. The decade was also defined by the biomedical response to the HIV/AIDS epidemic following the identification of the human immunodeficiency virus in 1983 and 1984 by Luc Montagnier, Françoise Barré-Sinoussi and Robert Gallo. Additionally, recombinant human insulin, approved in 1982, became the first commercially available medication produced through recombinant DNA technology.
Sources: en.wikipedia.org
=== Speed of change === VVM types are indicated by a number after "VVM". The number refers to the number of days required for the VVM to reach the discard-point (circle) color at 37 °C (99 °F). For example, VVM7 takes 7 days to turn at 37 degrees. Four main types are in use to match to the degradation rates of different vaccines: VVM30 (HepB, BCG, tetanus), VVM14 (measles, MMR), VVM7 (DPT), and VVM2 (OPV). VVM11 and VVM250 are also available. VVMs work because almost every chemical reaction corresponds to the Arrhenius equation, exponentially speeding up as the temperature increases. When time-to-change-color for a VVM or the time-to-degrade for a vaccine are plotted against the temperature on an log-linear plot, the points tend to fall in a straight line as predicted by Arrhenius (Arrhenius graph). The straight line can therefore be used to both interpolate and extrapolate the time-to-change/degrade at any given temperature. To choose the right VVM for a vaccine, one matches the known vaccine endurance data points against an Arrhenius graph of VVMs.
=== Clipfish === Over the centuries, several variants of dried fish have evolved. Stockfish, dried as fresh fish and not salted, is often confused with clipfish, in which the fish is salted before drying. After 2–3 weeks in salt the fish has saltmatured and is transformed from wet salted fish to clipfish through a drying process. The salted fish was earlier dried on rocks (clips) on the foreshore. The production method for clipfish (or bacalhau in Portuguese) was developed by the Portuguese, who first mined salt near the brackish water of Aveiro and brought it to Newfoundland, where cod was available in tremendous quantities. Salting was not economically feasible until the 17th century, when cheap salt from southern Europe became available to the maritime nations of northern Europe. Stockfish is cured in a process called fermentation in which cold-adapted bacteria matures the fish, similar to the maturing process of cheese. Clipfish is processed in a chemical curing process called saltmaturing, similar to the maturing processes of other saltmatured products like Parma ham.
==== Chemistry ==== UV/Vis spectroscopy is widely used as a technique in chemistry to analyze chemical structure, the most notable one being conjugated systems. UV radiation is often used to excite a given sample where the fluorescent emission is measured with a spectrofluorometer. In biological research, UV radiation is used for quantification of nucleic acids or proteins. In environmental chemistry, UV radiation could also be used to detect Contaminants of emerging concern in water samples. In pollution control applications, ultraviolet analyzers are used to detect emissions of nitrogen oxides, sulfur compounds, mercury, and ammonia, for example in the flue gas of fossil-fired power plants. Ultraviolet radiation can detect thin sheens of spilled oil on water, either by the high reflectivity of oil films at UV wavelengths, fluorescence of compounds in oil, or by absorbing of UV created by Raman scattering in water. UV absorbance can also be used to quantify contaminants in wastewater. Most commonly used 254 nm UV absorbance is generally used as a surrogate parameters to quantify NOM. Another form of light-based detection uses an excitation-emission matrix (EEM) to detect and identify contaminants based on their fluorescence properties. EEM could be used to discriminate different groups of NOM based on the difference in light emission and excitation of fluorophores. NOMs with certain molecular structures are reported to have fluorescent properties in a wide range of excitation/emission wavelengths.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.